Dose-dependent metabolic effect of zoledronate on primary human osteoblastic cell cultures

Clinical and Experimental Rheumatology

Volumn 28, Issue 6, 2010, Pages 873-879

  Corrado, A ^a   Neve, A ^a   Maruotti, N ^a   Gaudio A ^a   Marucci, A ^a   Cantatore, F P ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Bisphosphonates; Osteoblasts

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ALKALINE PHOSPHATASE; CALCITRIOL; CASPASE 3; OSTEOCALCIN; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE; VITAMIN D;

ADULT; AGED; APOPTOSIS; ARTICLE; BONE DENSITY; BONE MARROW BIOPSY; CANCELLOUS BONE; CELL ACTIVITY; CELL METABOLISM; CELL PROLIFERATION; CELL VIABILITY; COLORIMETRY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IN VITRO STUDY; MALE; MICROENVIRONMENT; NORMAL HUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN SYNTHESIS; CELL CULTURE; CELL SURVIVAL; CYTOLOGY; DOSE RESPONSE; METABOLISM; MIDDLE AGED;

ADULT; AGED; ALKALINE PHOSPHATASE; APOPTOSIS; BONE DENSITY CONSERVATION AGENTS; CASPASE 3; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; OSTEOBLASTS; OSTEOCALCIN; VITAMIN D;

EID: 79952733060     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. FLEISCH H: Development of bisphosphonates: Breast Cancer Res 2002; 4: 30-4.
2. JUNG A, BISAZ S, FLEISCH H: The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals. Calcif Tissue Res 1973; 11: 269-80.
3. FRANCIS MD, RUSSEL RGG, FLEISCH H: Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science 1969; 165: 1264-6.
4. FLEISCH H, RUSSEL RGG, FRANCIS MD: Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 1969; 165: 1262-4.
5. FLEISCHH: Bisphosphonates: mechanism of action. Endocr Rev 1998; 19: 80-100.
6. ROUSIERE M, MICHOU L, CORNELIS F, ORCEL P: Paget's disease of bone. Best Pract Res Clin Rheumatol 2001; 17: 1019-41.
7. ZAIDI M, TURNER CH, CANALIS E et al:. Bone loss or lost bone: rationale and recommendations for the diagnosis and treament of early postmenopausal bone loss. Curr Osteoporos Res 2009; 7: 118-26.
8. LINN A, YUKSEL N, JUBY A, SADOWSKI CA: Osteoporosis treatment on older adults undergoing rehabilitation post-hip fracture. Clin Exp Rheumatol 2009; 27: 277-83.
9. BODY JJ, MANCINI I: Bisphosphonates for cancer patients: why, how and when? Support Care Cancer 2002; 10: 399-407.
10. CORRADO A, SANTORO N, CANTATORE FP: Extra-skeletal effects of bisphosphonates. Joint Bone Spine 2007; 74: 32-8.
11. D'ANGELO S, PADULA A, NIGRO A et al:. Italian evidence-based recommendations for the management of ankylosing spondylitis: the 3E initiative in rheumatology. Clin Exp Rheumatol 2008; 26: 1005-11.
12. MARCO PUCHE A, CALVO PENADES I, LOPEZ MONTESINOS B: Effectiveness of treatment with intravenous Pamidronate for calcinosis in juvenile dermatomyositis. Clin Exp Rheumatol 2010; 28: 135-40.
13. COLINA M, LA CORTE R, TROTTA F: Sustained remission of SAPHO syndrome with Pamidronate: a follow-up of fourteen cases and a review of the literature. Clin Exp Rheumatol 2009; 27: 115.
14. RUSSEL RGG, ROGERS MJ: Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999; 97: 97-106.
15. ROGERS MJ, FRITH JC, LUCKMAN SP et al:. Molecular mechanism of action of bisphosponates. Bone 1999; 24: 73-9.
16. PAN B, TO LB, FARRUGIA AN et al:. The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro. Bone 2004; 34: 112-23.
17. IM GI, QURESHI SA, KENNEY J et al:. Osteoblast proliferation and maturation by bisphosphonates. Biomaterials 2004; 25: 4105-15.
18. BUKOWSKY JF, DASCHER CC, DAS H: Alternative bisphosphonate targets and mechanisms of action. Biochem Byophis Res Commun 2005; 328: 746-50.
19. BLACK DM, DELMAS PD, EASTELL R et al.: Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809-22.
20. RECKER RR, DELMAS PD, HALSE J et al: Effects of intravenous Zoledronic Acid once yearly on bone remodelling and bone structure. J Bone Min Res 2008; 23: 1-16.
21. Lafage MH, Balena R, Battle MA et al: Comparison of alendronate and sodium fluoride effects on cancellous and cortical bone in minipigs. J Clin Invest 1995; 95: 212733.
22. BOYCE RW, PADDOK CL, GLEASON JR, SLETSEMA WK, ERIKSEN EF: The effects of risedronate on canine cancellous bone remodeling: three dimensional kinetic reconstrution of the remodeling site. J Bone Miner Res 1995; 20: 211-21.
23. ALLEN MR, IWATA K, PHIPPS R, BURR DB: Alterations in canine vertebral bone turnover, microdamage accumulation and biochemical properties following 1-year treatment with clinical doses of risedronate or alendronate. Bone 2006; 39: 872-9.
24. IWATA K, LI J, FOLLET H, PHIPPS R, BURR DB: Bisphosphonates suppress periosteal osteoblast activity independently of resorption in rat femur and tibia. Bone 2006; 39: 1053-8.
25. Parfitt AM, Drezner MK, Glorieux FH et al.: Bone histomorphometry: standardization of nomenclature, symbols and units. Report of the ASBMR histomorphometry nomenclasture committee. J Bone Min Res 1987; 2: 595-610.
26. REINHOLZ GG, GETZ B, PEDERSON L et al:. Bisphosphonates directly regulate cell prliferation, differentiation and gene expression in human osteoblasts. Cancer Res 2000; 60: 6001-7.
27. VON KNOCH F, JAUIERY C, KOWALSKY M et al.: Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stomal cells. Biomaterials 2005; 26: 6941-9.
28. SATO M, GRASSER W, ENDO N et al.: Bisphosphonate action: Alendronate localization in rat bone and effect on osteoclast ultrastructure. J Clin Invest 1991; 88: 2095-105.
29. MASTAGLIA SR, PELLEGRINI GG, MANDALUNIS PM, GONZALES CHAVES MM, FRIEDMAN SM, ZENI SN: Vitamin D insufficiency reduces the protective effect of bisphosphonate on ovariectomy-induced bone loss in rats. Bone 2006; 39: 837-44.
30. ADAMI S, GIANNINI S, BIANCHI G et al:. Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporos Int 2009; 20: 239-44.
31. DEANE A, CONSTANCIO L, FOGELMAN I, HAMPSON G: The impact of Vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal ostoporosis. BMC Musculoskelet Disord 2007; 10: 1-8.
32. RAO MV, BERK J, ALMOJALY SA, GOODLOE LII S, SULLIVAN M, DZIAK R: Effects of platelet-derived growth factor, vitamin D and parathyroid hormone on osteoblasts derived from cancer patients on chronic bisphosphonate therapy. Int J Mol Med 2009; 23: 407-13.
33. DWORETZKY SI, FEY EG, PENMAN S, LIAN JB, STEIN JL, STEIN GS: Progressive changes in the protein composition of the nuclear matrix during rat osteoblast differentiation. Proc Natl Acad Sci USA 1990; 87: 4605-9.
34. IDRIS AI, ROJAS J, GREIG IR, VAN'T HOF R, RALSTON SH: Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro. Calcif Tissue Int 2008; 82: 191-201.
35. FREDIANI B, SPREAFICO A, CAPPERUCCI C et al.: Long term effect of neridronate on human osteoblastic cell cultures. Bone 2004; 35: 859-69.
36. IGARASHI K, HIRAFUJI M, ADACHI H, SHINODA H, MITANI H: Effects of bisphosphonates on phosphatase alkaline activity, mineralization, prostaglandin E2 synthesis in the clonal osteoblast-like cell line MC3T3-E1. Prostaglandins Leukot Essent Fatty Acids 1997; 56: 121-5.
37. XIONG Y, YANG HJ, FENG J, SHI ZL, WU LD: Effects of alendronate on the proliferation and osteogenic differentiation of MG-63 cells. J Inter Med Res 2009; 37: 407-16.
38. GIULIANI N, PEDRAZZONI G, PASSERI G, GIRASOLE G: Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo. Bone 1998; 22: 455-61.
39. D'Aoust P, Mcculloch CA, Tenenbaum HC, Lekic PC: Etidronate (EEBP) promotes osteoblast differentiation and wound closure in rat calvaria. Cell Tissue Res 2000; 302: 353-63.
40. ITOH F, AOYAGI H, FURIHATA-KOMATSU H et al.: Clodronate stimulates osteoblast differentiation in ST2 and MC3T3-E1 cells and rat organ cultures. Eur J Pharmacol 2003; 477: 9-16.
41. GARCIA-MORENO C, SERRANO S, NACHER M et al.: Effect of alendronate on cultured normal human osteoblasts. Bone 1998; 22: 233-9.